



Press Release – Stuttgart, Germany & Basel, Switzerland July 18th 2006

Genedata and Insilico Biotechnology in Systems Biology Collaboration

Genedata and Insilico Biotechnology will work together using systems biology to support life science companies enhance their biotechnological production methods. The collaboration will combine Genedata's computational systems for genomics data management and analysis with Insilico's pathway simulation tools.

Systems biology probes the workings of biological pathways using a combination of simulation techniques and genome-wide, high throughput data. The approach finds application in fields such as metabolic engineering and nutrigenomics, and is increasingly used for disease modeling and in drug discovery.

The collaboration between Genedata and Insilico will focus on biotechnological challenges in the fine chemical, food, feed and personal care sectors. Target applications include guiding the development of high-performance microbial production strains used in industrial fermentation. The collaboration will support life science research, for example, at Degussa and the Kluyver Centre for Genomics and Industrial Fermentation.

"Our industrial partners seek closer integration between high throughput molecular data and the simulation tools used to engineer novel production strains", explained Dr. Othmar Pfannes, CEO of Genedata. Genedata has developed a systems biology platform for integrating pathway information with genome-wide expression data.

"There is a growing need for integrated and predictive methods to exploit -omics data", explained Klaus Mauch, CEO of Insilico Biotechnology. Insilico has developed a software application suite, Insilico Discovery, to set-up and simulate large scale metabolic network models. Klaus Mauch added, "We are proud to link our modeling and simulation tools with Genedata's data management platform. Customers will benefit from novel, time- and cost-effective information that exceeds the limits of conventional approaches".

Contact

Genedata AG
Dr. Tobe Freeman
Manager Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com

Insilico Biotechnology GmbH
Klaus Mauch
CEO
+49 711 674 2164
+49 711 674 2166
klaus.mauch@insilico-biotechnology.com
www.insilico-biotechnology.com

Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com.

Insilico Biotechnology predicts and optimizes biotechnological processes for the chemical, food, agro, and healthcare industries. Successful in business since 2001, Insilico provides internationally renowned expertise and unique technology platforms. Insilico's competitive advantage is its proven track record of producing new insights and IP for customers in systems biology using its proprietary software, databases and computing facilities. By building better and innovative integrated models of complex cellular processes, Insilico sets new standards in systems biology as a leading solution provider to the Life Sciences industries. Insilico's expertise derives from several research laboratories and the company's co-founders. Insilico is a privately-owned company, located in Stuttgart, Germany. For more information about Insilico , please visit: www.insilico-biotechnology.com/.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.